Comparison of PD-L1 and B7-H3 in Cancer Immunotherapy

PD-L1 and PD-1 inhibitors have achieved great success in the treatment of patients of a wide spectrum of cancers. However, only a fraction of cancer patients benefits from this therapy. Therefore, it is quite urgent to find another target for immunotherapy. Recently we published one article (Young-hee Lee et al., Cell Research, 2017, 27: 1034-104), which showed that B7-H3 knockout mice and the mice treated with anti-B7-H3 neutralizing antibody displayed slower tumor growth in several tumor types. More interestingly, combining blockade of B7-H3 and PD-1 resulted in synergistic effect on inhibition of tumor growth. So in this paper, we compare PD-L1 and B7-H3 in the terms of expression pattern, mechanism of action, the sites of action in tumor evasion and clinical inhibitors. These suggest that B7-H3 is a promising target for cancer immunotherapy.

Author(s): Ling Ni

Abstract | Full-Text | PDF

Share This Article